Immunotherapy Resistance and Response to Adoptive Therapy in Patients With Metastatic Uveal Melanoma
Researchers may have uncovered the mechanisms behind conventional immunotherapy resistance as well as the efficacy of adoptive therapy in metastatic uveal melanoma...
Cisplatin, Gemcitabine, and IMRT in Locally Advanced Vulvar Cancer
In a phase II trial (NRG Oncology/GOG Study 279) reported in the Journal of Clinical Oncology, Horowitz et al found that concurrent cisplatin, gemcitabine...
HER2-Positive Early Breast Cancer: PET-Based, pCR-Adapted Strategy
In the phase II PHERGain trial reported in The Lancet, Pérez-García et al found that a positron-emission tomography (PET)-based, pathologic complete response...
A Pioneering Female Oncologist in Morocco Helps Advance the Global Shift Toward Gender Equity in Academia
Success stories in research, advocacy, and education from low- and middle-income countries deserve international recognition to motivate the next generation...
Giredestrant in Previously Treated Patients With ER-Positive, HER2-Negative Advanced Breast Cancer
In the phase II acelERA BC trial reported in the Journal of Clinical Oncology, Miguel Martín, MD, PhD, and colleagues found that the selective estrogen receptor (ER)...
Susan Faye Dent: Cardio-Oncology Is a Growing Subspecialty, but Where Are the Oncologists?
Kelly Hewitt and Laura J. Esserman: Reframing DCIS as an Opportunity for Cancer Prevention
Garth Strohbehn, Allen Lichter, and Mark Ratain: Sotorasib, the Poster Child for Project Optimus
Kevin B. Knopf and Charles L. Bennett: Generic Drug Shortages and Essential Cancer Medicines
Stuart M. Lichtman: All Adult Oncologists Are Geriatric Oncologists
Sponsored Content
SPONSORED BY LILLY MEDICAL AFFAIRS
Targeting Rare, Actionable Alterations in Advanced Non–Small Cell Lung Cancer
Choice of First-Line Platinum Chemotherapy Does Not Significantly Impact Efficacy of Second-Line Immunotherapy in Advanced Urothelial Carcinoma
In a presentation of real-world data given during the 2021 ASCO Annual Meeting, Miron et al concluded that the choice of first-line platinum chemotherapy did not result in a significant difference in overall survival benefit among patients with advanced bladder cancer who were able to go on to...
Impact of Genes on Total Number and Type of Nevi
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
Venetoclax Plus FLAG-IDA Induction and Consolidation for AML
In a single-institution phase I/II study reported in the Journal of Clinical Oncology, Courtney D. DiNardo, MD, and colleagues found that the combination of venetoclax with FLAG-IDA (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin) in induction and consolidation...
OUTBACK Trial: No Survival Benefit With Adjuvant Chemotherapy After Standard Chemoradiation for Locally Advanced Cervical Cancer
Cervical cancer is the fourth most common cancer in women worldwide, and the leading cause of cancer-related death among women in Eastern, Western, Middle, and Southern Africa. Globally, in 2018, approximately 570,000 women were diagnosed with cervical cancer, and 311,000 women died. In the United...
Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma
In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...
Real-World Survival Outcomes With Various Treatment Regimens for Metastatic Renal Cell Carcinoma
In a real-world retrospective propensity-matched cohort study reported in JAMA Network Open, Chakiryan et al found that both first-line immunotherapy and combined treatment with targeted therapy plus immunotherapy were associated with improved overall survival vs targeted therapy alone in patients...
Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...
